HPV vaccination provides protection for immunocompromised children

A quadrivalent human papillomavirus vaccine provided adequate seroconversion response rates in immunocompromised children, according to Dr. C. Raina MacIntyre, MBBS, PhD, and her associates. In a clinical trial of 59 immunocompromised children aged 5-18, seroconversion rates for HPV types 6, 11,...
Source: Skin and Allergy News - Category: Dermatology Source Type: news